{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:27:05Z","timestamp":1790645225772,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6\u201359\u00a0months old were monitored for 42\u00a0days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64\u201383%) in Nanoro, 76% (66\u201383%) in Gourcy, and 92% (84\u201396%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75\u201389%) in Gourcy, 89% (81\u201394%) in Nanoro, and 97% (92\u201399%) in Niangoloko.<\/jats:p>\n                    <jats:p>\n                      No\n                      <jats:italic>Pfk13<\/jats:italic>\n                      mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      gene. There was also no association observed between treatment outcome and\n                      <jats:italic>Pfpm2<\/jats:italic>\n                      or\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      copy number variation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registry<\/jats:italic>\n                      Pan African Clinical Trial Registry Identifier: PACTR201708002499311.\n                    <\/jats:p>\n                    <jats:p>Date of registration: 8\/3\/2017<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/Search.aspx\">https:\/\/pactr.samrc.ac.za\/Search.aspx<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03585-6","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T15:03:14Z","timestamp":1611068594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"pactr201708002499311","registry":"10.18810\/pactr"}],"author":[{"given":"Adama","family":"Gansan\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah F.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidore","family":"Yerbanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperance","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Kinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casimir","family":"Tarama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madou","family":"Tapsoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kangoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheick Said","family":"Compaore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmane","family":"Badolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blami","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Tchwenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Valea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"3585_CR1","doi-asserted-by":"publisher","DOI":"10.30875\/7e6f8c91-en","volume-title":"World malaria report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. World malaria report 2019. Geneva: World Health Organization; 2019."},{"key":"3585_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12936-017-1715-1","volume":"16","author":"A Diallo","year":"2017","unstructured":"Diallo A, Si\u00e9 A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal. Malar J. 2017;16:63.","journal-title":"Malar J"},{"key":"3585_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/infdis\/jiv370","volume":"213","author":"AL Ou\u00e9draogo","year":"2016","unstructured":"Ou\u00e9draogo AL, Gon\u00e7alves BP, Gn\u00e9m\u00e9 A, Wenger EA, Guelbeogo MW, Ou\u00e9draogo A, et al. Dynamics of the human infectious reservoir for malaria determined by mosquito feeding assays and ultrasensitive malaria diagnosis in Burkina Faso. J Infect Dis. 2016;213:90\u20139.","journal-title":"J Infect Dis"},{"key":"3585_CR4","volume-title":"Drug resistance in malaria","author":"PB Bloland","year":"2001","unstructured":"Bloland PB. Drug resistance in malaria. Geneva: World Health Organization; 2001."},{"key":"3585_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3185\/pathexo3235","volume":"102","author":"A Gansan\u00e9","year":"2009","unstructured":"Gansan\u00e9 A, N\u00e9bi\u00e9 I, Soulama I, Tiono A, Diarra A, Konat\u00e9 AT, et al. [Change of antimalarial first-line treatment in Burkina Faso in 2005](in French). Bull Soc Path Exot. 2009;102:31\u20135.","journal-title":"Bull Soc Path Exot"},{"key":"3585_CR6","first-page":"S1","volume":"95","author":"A Gansan\u00e9","year":"2005","unstructured":"Gansan\u00e9 A, Nebi\u00e9 I, Diarra A, Quedraogo A, Soulama I, Bougouma E, et al. Efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ouagadougou, capital city of Burkina Faso. Acta Trop. 2005;95:S1.","journal-title":"Acta Trop"},{"key":"3585_CR7","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3585_CR8","volume-title":"Policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa","author":"WHO","year":"2012","unstructured":"WHO. Policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva: World Health Organization; 2012."},{"key":"3585_CR9","volume-title":"Directives nationales pour la prise en charge du paludisme dans les formations sanitaires du Burkina Faso","author":"Programme National de Lutte contre le Paludisme","year":"2017","unstructured":"Programme National de Lutte contre le Paludisme. Directives nationales pour la prise en charge du paludisme dans les formations sanitaires du Burkina Faso. Ouagadougou: Minist\u00e8re de la Sant\u00e9; 2017."},{"key":"3585_CR10","doi-asserted-by":"publisher","first-page":"a025619","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harbor Perspect Med. 2017;7:a025619.","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"3585_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jgar.2015.02.002","volume":"3","author":"C Severini","year":"2015","unstructured":"Severini C, Menegon M. Resistance to antimalarial drugs: An endless world war against Plasmodium that we risk losing. J Glob Antimicrob Resist. 2015;3:58\u201363.","journal-title":"J Glob Antimicrob Resist"},{"key":"3585_CR12","volume-title":"Artemisinin resistance and artemisinin-based combination therapy efficacy: status report","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva: World Health Organization; 2018."},{"key":"3585_CR13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med."},{"key":"3585_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg."},{"key":"3585_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"3585_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"3585_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin\u2013piperaquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"key":"3585_CR18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1473-3099(17)30365-1","volume":"17","author":"OA Koita","year":"2017","unstructured":"Koita OA, Sangar\u00e9 L, Miller HD, Sissako A, Coulibaly M, Thompson TA, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017;17:1266\u201375.","journal-title":"Lancet Infect Dis"},{"key":"3585_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12916-016-0716-1","volume":"14","author":"L Denoeud-Ndam","year":"2016","unstructured":"Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Diawara H, et al. Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Med. 2016;14:167.","journal-title":"BMC Med"},{"key":"3585_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13149-012-0209-6","volume":"105","author":"M Siribi\u00e9","year":"2012","unstructured":"Siribi\u00e9 M, Diarra A, Tiono A, Soulama I, Sirima S. Efficacit\u00e9 de l\u2019art\u00e9m\u00e9ther-lum\u00e9fantrine dans le traitement du paludisme simple de l\u2019enfant en milieu rural au Burkina Faso en 2009. Bull Soc Path Exot. 2012;105:202\u20137.","journal-title":"Bull Soc Path Exot"},{"key":"3585_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12936-015-0843-8","volume":"14","author":"P Sondo","year":"2015","unstructured":"Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, et al. Effectiveness and safety of artemether\u2013lumefantrine versus artesunate\u2013amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malar J. 2015;14:325.","journal-title":"Malar J"},{"key":"3585_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/tmi.12274","volume":"19","author":"H Tinto","year":"2014","unstructured":"Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A, et al. Effectiveness of artesunate\u2013amodiaquine vs. artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Trop Med Int Health. 2014;19:469\u201375.","journal-title":"Trop Med Int Health."},{"key":"3585_CR23","first-page":"2018","volume-title":"Annuaire statistique Ouagadougou","author":"DGESS","year":"2018","unstructured":"DGESS. Annuaire statistique Ouagadougou. Burkina Faso: Minist\u00e8re de la Sant\u00e9; 2018. p. 2018."},{"key":"3585_CR24","volume-title":"Toxicity grading scale for determining the severity of adverse events","author":"WHO","year":"2003","unstructured":"WHO. Toxicity grading scale for determining the severity of adverse events. Geneva: World Health Organization; 2003."},{"key":"3585_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/1475-2875-12-405","volume":"12","author":"L Canier","year":"2013","unstructured":"Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for moving malaria PCR detection of parasite reservoir into the field. Malar J. 2013;12:405.","journal-title":"Malar J"},{"key":"3585_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0169-4758(98)01340-4","volume":"14","author":"G Snounou","year":"1998","unstructured":"Snounou G, Beck H. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Tdy. 1998;14:462\u20137.","journal-title":"Parasitol Tdy"},{"key":"3585_CR27","unstructured":"WHO, MMV. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. Geneva, World Health Organization, 2008. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241596305\/en\/"},{"key":"3585_CR28","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"3585_CR29","unstructured":"WHO. Tools for monitoring antimalarial drug efficacy. Geneva, World Health Organization, 2019. http:\/\/www.who.int\/malaria\/areas\/drug_resistance\/efficacy-monitoring-tools\/en\/. Accessed 13 Jun 2020."},{"key":"3585_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1098\/rstb.1999.0426","volume":"354","author":"N White","year":"1999","unstructured":"White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354:739\u201349.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"3585_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/1475-2875-9-366","volume":"9","author":"SD Fernando","year":"2010","unstructured":"Fernando SD, Rodrigo C, Rajapakse S. The, \u201chidden\u201d burden of malaria: cognitive impairment following infection. Malar J. 2010;9:366.","journal-title":"Malar J"},{"key":"3585_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4269\/ajtmh.12-0560","volume":"88","author":"EM Foote","year":"2013","unstructured":"Foote EM, Sullivan KM, Ruth LJ, Oremo J, Sadumah I, Williams TN, et al. Determinants of anemia among preschool children in rural, Western Kenya. Am J Trop Med Hyg. 2013;88:757\u201364.","journal-title":"Am J Trop Med Hyg"},{"key":"3585_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.aogh.2015.01.003","volume":"80","author":"S McCuskee","year":"2014","unstructured":"McCuskee S, Brickley EB, Wood A, Mossialos E. Malaria and macronutrient deficiency as correlates of anemia in young children: a systematic review of observational studies. Ann Glob Health. 2014;80:458\u201365.","journal-title":"Ann Glob Health"},{"key":"3585_CR34","unstructured":"WHO Prequalification of Medicines Programme. Geneva: World Health Organization; 2020. Accessed 20 Jul 2020."},{"key":"3585_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","volume":"16","author":"I Sagara","year":"2016","unstructured":"Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16:189\u201398.","journal-title":"Lancet Infect Dis"},{"key":"3585_CR36","unstructured":"COARTEM\u00ae(artemether and lumefantrine) tablets, for oral use. Novartis Pharmaceuticals Corporation; 2019."},{"key":"3585_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, van Vugt M, Ezzet FD. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37:105\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"3585_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12874-019-0856-z","volume":"19","author":"P Dahal","year":"2019","unstructured":"Dahal P, Stepniewska K, Guerin PJ, D\u2019Alessandro U, Price RN, Simpson JA. Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting. BMC Med Res Methodol. 2019;19:215.","journal-title":"BMC Med Res Methodol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03585-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03585-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03585-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:28:36Z","timestamp":1628598516000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03585-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3585"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03585-6","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Ethics Committee of CNRFP and the Health Research Ethics Committee of Burkina Faso and was conducted in accordance with International Conference on Harmonization and Good Clinical Practices. The study was approved by the Regulatory authority from the Ministry of Health. Parents or guardians provided written informed consent for their children to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}